about
Targeting Cancer Metabolism - Revisiting the Warburg EffectsChinese Herbs Interfering with Cancer Reprogramming MetabolismRole of multifaceted regulators in cancer glucose metabolism and their clinical significanceOvarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reductionSodium MRI of glioma in animal models at ultrahigh magnetic fields.Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithineFeasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer.Multiple functions of hypoxia-regulated miR-210 in cancer.Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples.Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signalingGlucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines.Influence of Preoperative Serum Aspartate Aminotransferase (AST) Level on the Prognosis of Patients with Non-Small Cell Lung Cancer.Pinin associates with prognosis of hepatocellular carcinoma through promoting cell proliferation and suppressing glucose deprivation-induced apoptosis.DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis.Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cellsType 2 diabetes mellitus and risk of gallbladder cancer: a systematic review and meta-analysis of observational studies.The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticlesNoncoding RNAs in Regulation of Cancer Metabolic Reprogramming.Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer.Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer.PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cellsPLD1 overexpression promotes invasion and migration and function as a risk factor for Chinese glioma patients.Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel.Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancerPTEN deficiency and mutant p53 confer glucose-addiction to thyroid cancer cells: impact of glucose depletion on cell proliferation, cell survival, autophagy and cell migration.Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.Two-color vibrational imaging of glucose metabolism using stimulated Raman scattering.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.
P2860
Q26738876-FC77001D-010F-43D7-85BC-3EF5F1EE8120Q26744552-647314F4-CA09-4517-A4EC-068ED8564032Q26765039-E391E08F-F500-4413-8D4A-7A5B9ADC845FQ26786610-FD98A261-6406-4AC5-9CA7-172614BD1402Q30980381-BB38F549-9070-44A9-9F96-7CFE74442C44Q33598120-D1F186EE-1A96-47F3-9CC6-7C6675F06EC3Q33598925-0C0AE862-945C-4AE9-98E6-B5A4AC447793Q33765128-7EAB9A02-5A21-4AD5-A3CF-686D3F7E50B3Q33844930-F3A56C06-A6EA-47B3-989D-90B7DB1D0BFDQ36354442-C9698107-B05A-457E-A908-3A8B16D40B76Q36525420-22442D89-EAAA-4CF3-B58E-CFA51A5BC039Q37286453-B869290B-AAB6-4B5F-B144-C2F1ACD5FEEAQ37457638-5C07531B-536E-4507-86A1-3F945656508BQ37702777-21498DB1-7FED-40A4-A9A8-3CBF62D3FE2BQ37745233-E14340DA-4777-4F43-8EB3-C5901D85E379Q38537953-FD206D01-79C2-46A0-9121-9B6319BC4811Q38698128-BB0E1B5B-7176-4A5F-B31A-17CDB4854B73Q38833609-2EFA438A-C026-48CF-8394-F209E54703D2Q38885481-F4F636B3-9456-44D5-BD2E-46309262EC96Q39061667-5E582774-37D3-40AE-B96A-CCF1FFB27B64Q39078549-E98E3957-BC29-4168-A0CD-D7C5FDE43D8FQ39201094-251C1577-3BAB-45FB-BE9E-F1F6AC03F66EQ41343361-3BD80D45-8A14-4CEB-863B-D8F110889B28Q41592835-B9550EE1-F7FD-48E1-A1CA-2D0D825093FEQ41779719-C6199BE1-BABC-4C6A-9BAA-5FAFBC3DE6F6Q42071893-881D1EF8-6A5D-4872-83FA-BED0D94CCBB2Q46753862-39A33021-17E9-4FF2-9FD1-D509C72F64A1Q47927103-6559E091-7271-4C5A-A5CE-5E56BC1DFA4FQ50345931-8D03FD86-314A-4C02-8B96-9C5D4EF9BDFFQ53795029-5849E85E-0FF8-420E-A06A-7478191E37F5
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting glucose metabolism in patients with cancer.
@en
type
label
Targeting glucose metabolism in patients with cancer.
@en
prefLabel
Targeting glucose metabolism in patients with cancer.
@en
P2860
P356
P1433
P1476
Targeting glucose metabolism in patients with cancer.
@en
P2093
Shannon E Elf
P2860
P304
P356
10.1002/CNCR.28501
P407
P577
2013-12-02T00:00:00Z